Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor
December 02 2020 - 1:11PM
Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a
specialty life sciences company focused on the research and
development of therapeutics for medical needs and rare disorders,
is pleased to announce the appointment of Dr. Joel Moody, MD, MPH,
DTM&H, as a medical and clinical advisor to the Company to
assist in the expansion of clinical studies in Canada and the
clinical data analysis on the ongoing U.S. Food & Drug
Administration (“FDA”) Phase 3 clinical trial (the “Study”) to
evaluate the safety and efficacy of Bucillamine in patients with
mild-moderate COVID-19.
"We would like to welcome Dr. Moody as a medical
and clinical advisor to our team and we look forward to his
contributions in our ongoing FDA Phase 3 clinical study as well as
expanding our COVID-19 studies in Canada," said Michael Frank, CEO
of Revive. "Dr. Moody’s experience in clinical epidemiology, data
analysis and research are key to our FDA Phase 3 study as we gather
clinical data from patients enrolled.”
Dr. Moody stated: “I look forward to serving as
a medical and clinical advisor to Revive for both their FDA Phase 3
study and their expansion initiatives in Canada for clinical
studies in COVID-19.”
Dr. Joel Moody has over 15 years of experience
in clinical research in oncology (breast and ovarian cancer),
sickle cell disease, Human T-Lymphotrophic Virus, Types I and II,
cholera, and tuberculosis. He brings international expert knowledge
and experience in clinical and epidemiological studies. During his
career, Joel has helped to launch and manage global phase I - IV
clinical studies, including large scale morbid-mortality trials.
Joel trained in oncology, tropical and infectious diseases, and
internal medicine and completed fellowships at the
Lunenfeld-Tanenbaum Research Institute in Mount Sinai
Hospital/University of Toronto and the Instituto de Medicina
Tropical "Alexander von Humboldt"/ Universidad Peruana Cayetano
Heredia (Lima, Peru).
About Revive Therapeutics
Ltd. Revive
is a life sciences company focused on the research and development
of therapeutics for infectious diseases and rare disorders, and it
is prioritizing drug development efforts to take advantage of
several regulatory incentives awarded by the FDA such as Orphan
Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease
designations. Currently, the Company is exploring the use of
Bucillamine for the potential treatment of infectious diseases,
with an initial focus on severe influenza and COVID-19. With its
recent acquisition of Psilocin Pharma Corp., Revive is advancing
the development of Psilocybin-based therapeutics in various
diseases and disorders. Revive’s cannabinoid pharmaceutical
portfolio focuses on rare inflammatory diseases and the company was
granted FDA orphan drug status designation for the use of
Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and
to treat ischemia and reperfusion injury from organ
transplantation. For more information, visit
www.ReviveThera.com.
For more information, please contact:Michael
FrankChief Executive OfficerRevive Therapeutics Ltd.Tel: 1 888 901
0036Email: mfrank@revivethera.comWebsite: www.revivethera.com
Neither the Canadian Securities Exchange nor its
Regulation Services Provider have reviewed or accept responsibility
for the adequacy or accuracy of this release.Cautionary
Statement
This press release contains ‘forward-looking
information’ within the meaning of applicable Canadian securities
legislation. These statements relate to future events or future
performance. The use of any of the words “could”, “intend”,
“expect”, “believe”, “will”, “projected”, “estimated” and similar
expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking
information and are based on Revive’s current belief or assumptions
as to the outcome and timing of such future events. Forward looking
information in this press release includes information with respect
to the Offering, including the intended use of proceeds.
Forward-looking information is based on reasonable assumptions that
have been made by Revive at the date of the information and is
subject to known and unknown risks, uncertainties, and other
factors that may cause actual results or events to differ
materially from those anticipated in the forward-looking
information. Given these risks, uncertainties and assumptions, you
should not unduly rely on these forward-looking statements. The
forward-looking information contained in this press release is made
as of the date hereof, and Revive is not obligated to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. The foregoing statements expressly
qualify any forward-looking information contained herein. Reference
is made to the risk factors disclosed under the heading “Risk
Factors” in the Company’s annual MD&A for the fiscal year ended
June 30, 2020, which has been filed on SEDAR and is available under
the Company’s profile at www.sedar.com.
Revive Therapeutics (CSE:RVV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Revive Therapeutics (CSE:RVV)
Historical Stock Chart
From Oct 2023 to Oct 2024